Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone vs chlortalidone for arterial stiffness and left ventricular mass in stage 3 chronic kidney disease
2013-002636-25Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of spironolactone in chronic kidney disease (CKD) and cardiac morbidity (2 arms), sponsored by University of Birmingham. Primary endpoints: Change in arterial stiffness and Change in left ventricular mass. Started Aug 2013; status: completed.
02
Drugs
spironolactone
03
Conditions
chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2013-002636-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002636-25.